NO330924B1 - Isolert antistoff eller antistoffragment, immunokonjugat, anvendelse av et immunokonjugat, en terapeutisk effektiv mengde av et immunokonjugat eller et antistoff eller antistoffragment for fremstilling av preparater henholdsvis for selektiv odeleggelse av celler, behandling av en sykdomstilstand eller diagnostisering av metastaser eller prostatakreft, samt pavisningsmetode. - Google Patents

Isolert antistoff eller antistoffragment, immunokonjugat, anvendelse av et immunokonjugat, en terapeutisk effektiv mengde av et immunokonjugat eller et antistoff eller antistoffragment for fremstilling av preparater henholdsvis for selektiv odeleggelse av celler, behandling av en sykdomstilstand eller diagnostisering av metastaser eller prostatakreft, samt pavisningsmetode.

Info

Publication number
NO330924B1
NO330924B1 NO20022836A NO20022836A NO330924B1 NO 330924 B1 NO330924 B1 NO 330924B1 NO 20022836 A NO20022836 A NO 20022836A NO 20022836 A NO20022836 A NO 20022836A NO 330924 B1 NO330924 B1 NO 330924B1
Authority
NO
Norway
Prior art keywords
immunoconjugate
antibody
antibody fragment
diagnosis
metastasis
Prior art date
Application number
NO20022836A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022836D0 (no
NO20022836L (no
Inventor
Richard Harkins
Deborah Parkes
Gordon Parry
Douglas W Schneider
Renate Steinbrecher
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20022836D0 publication Critical patent/NO20022836D0/no
Publication of NO20022836L publication Critical patent/NO20022836L/no
Publication of NO330924B1 publication Critical patent/NO330924B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20022836A 1999-12-16 2002-06-14 Isolert antistoff eller antistoffragment, immunokonjugat, anvendelse av et immunokonjugat, en terapeutisk effektiv mengde av et immunokonjugat eller et antistoff eller antistoffragment for fremstilling av preparater henholdsvis for selektiv odeleggelse av celler, behandling av en sykdomstilstand eller diagnostisering av metastaser eller prostatakreft, samt pavisningsmetode. NO330924B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17237099P 1999-12-16 1999-12-16
US09/732,357 US6682902B2 (en) 1999-12-16 2000-12-07 DNA encoding a novel RG1 polypeptide
PCT/US2000/033901 WO2001044291A2 (en) 1999-12-16 2000-12-15 Polynucleotid encoding the rg1 polypeptide

Publications (3)

Publication Number Publication Date
NO20022836D0 NO20022836D0 (no) 2002-06-14
NO20022836L NO20022836L (no) 2002-08-15
NO330924B1 true NO330924B1 (no) 2011-08-22

Family

ID=26868022

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022836A NO330924B1 (no) 1999-12-16 2002-06-14 Isolert antistoff eller antistoffragment, immunokonjugat, anvendelse av et immunokonjugat, en terapeutisk effektiv mengde av et immunokonjugat eller et antistoff eller antistoffragment for fremstilling av preparater henholdsvis for selektiv odeleggelse av celler, behandling av en sykdomstilstand eller diagnostisering av metastaser eller prostatakreft, samt pavisningsmetode.

Country Status (32)

Country Link
US (5) US6682902B2 (enExample)
EP (2) EP2048157B1 (enExample)
JP (1) JP4979867B2 (enExample)
KR (1) KR100752434B1 (enExample)
CN (1) CN1297566C (enExample)
AT (1) ATE440862T1 (enExample)
AU (1) AU784674B2 (enExample)
BG (1) BG65898B1 (enExample)
BR (1) BR0017022A (enExample)
CA (1) CA2394574A1 (enExample)
CZ (1) CZ299232B6 (enExample)
DE (1) DE60042836D1 (enExample)
DK (1) DK1237915T3 (enExample)
EE (1) EE05293B1 (enExample)
ES (1) ES2331106T3 (enExample)
HR (1) HRP20020549B1 (enExample)
HU (1) HU229001B1 (enExample)
IL (2) IL150115A0 (enExample)
LT (1) LT5046B (enExample)
ME (1) MEP37808A (enExample)
MX (1) MXPA02005914A (enExample)
NO (1) NO330924B1 (enExample)
NZ (1) NZ519598A (enExample)
PL (1) PL207634B1 (enExample)
PT (1) PT1237915E (enExample)
RO (1) RO122543B1 (enExample)
RS (1) RS50831B (enExample)
RU (1) RU2283130C2 (enExample)
SI (2) SI21140A (enExample)
SK (2) SK286384B6 (enExample)
WO (1) WO2001044291A2 (enExample)
ZA (1) ZA200205638B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020161199A1 (en) * 1998-04-08 2002-10-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
NZ528700A (en) * 1998-04-08 2005-02-25 Genentech Inc Novel PRO866 polypeptides and nucleic acids with homology to mindin and spondin proteins
US6960433B1 (en) 1998-10-19 2005-11-01 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US20070031901A1 (en) * 1999-03-08 2007-02-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
PE20050712A1 (es) * 2003-07-22 2005-11-02 Schering Ag Anticuerpos rg1
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
TWI494319B (zh) * 2007-02-21 2015-08-01 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
JP2011505371A (ja) * 2007-11-30 2011-02-24 ブリストル−マイヤーズ スクイブ カンパニー 抗−ｒｇ−１抗体の複合体
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
CN102346184B (zh) * 2010-08-03 2014-03-26 中国人民解放军军事医学科学院生物工程研究所 Spon2的新用途
DE202012012998U1 (de) 2011-08-31 2014-06-13 Daniel Elias Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5437994A (en) 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2135499A1 (en) 1992-05-14 1993-11-25 James D. Thompson Method and reagent for inhibiting cancer development
US5871969A (en) 1996-02-12 1999-02-16 Human Genome Sciences, Inc. Nucleic acids encoding human neuronal attachment factor-1
US6287777B1 (en) 1996-05-10 2001-09-11 Beth Israel Deaconess Medical Center NPG-1 gene that is differentially expressed in prostate tumors
US6177244B1 (en) 1996-05-10 2001-01-23 Beth Israel Deaconess Medical Center Inc. NPG-1 gene that is differentially expressed in prostate tumors
US5804382A (en) 1996-05-10 1998-09-08 Beth Israel Deaconess Medical Center, Inc. Methods for identifying differentially expressed genes and differences between genomic nucleic acid sequences
JP3494529B2 (ja) * 1996-06-06 2004-02-09 Ｙｋｋ株式会社 一体成形面ファスナー
AU4236297A (en) * 1996-08-26 1998-03-19 University Of Washington Therapeutic and diagnostic applications of perlecan domain splice variants
AU6961398A (en) 1997-04-10 1998-10-30 Zymogenetics Inc. Secreted f-spondin homologs
AU745787B2 (en) * 1997-05-06 2002-03-28 Human Genome Sciences, Inc. Enterococcus faecalis polynucleotides and polypeptides
JP2001500386A (ja) 1997-05-09 2001-01-16 スミスクライン ビーチャム コーポレーション インテグリンリガンドであるヒトＭｉｎｄｉｎ
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
US6166176A (en) * 1998-03-17 2000-12-26 Immvarx, Inc. Cancer marker protein and peptides thereof
US6960433B1 (en) * 1998-10-19 2005-11-01 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
JP2002527757A (ja) * 1998-10-19 2002-08-27 ダイアデクスアス・インコーポレーテッド 前立腺癌を診断、監視、病期分類、イメージング及び治療する方法
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US6824780B1 (en) * 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
US6682902B2 (en) 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide

Also Published As

Publication number Publication date
PT1237915E (pt) 2009-11-04
RS50831B (sr) 2010-08-31
KR100752434B1 (ko) 2007-08-27
ES2331106T3 (es) 2009-12-22
PL356220A1 (en) 2004-06-28
EP1237915A2 (en) 2002-09-11
US20040152139A1 (en) 2004-08-05
AU784674B2 (en) 2006-05-25
HUP0204224A3 (en) 2004-12-28
CN1434832A (zh) 2003-08-06
BR0017022A (pt) 2002-11-05
AU3074601A (en) 2001-06-25
NO20022836D0 (no) 2002-06-14
HRP20020549B1 (hr) 2013-09-30
EP2048157A1 (en) 2009-04-15
LT2002070A (en) 2003-04-25
SI1237915T1 (sl) 2009-12-31
LT5046B (lt) 2003-08-25
YU44602A (sh) 2005-06-10
US20090292112A1 (en) 2009-11-26
EP2048157B1 (en) 2012-10-10
KR20020065575A (ko) 2002-08-13
RO122543B1 (ro) 2009-08-28
MEP37808A (en) 2011-05-10
ZA200205638B (en) 2003-10-15
CA2394574A1 (en) 2001-06-21
HRP20020549A2 (en) 2004-04-30
SK8482002A3 (en) 2003-02-04
HUP0204224A2 (hu) 2003-03-28
SI21140A (sl) 2003-08-31
US7307154B2 (en) 2007-12-11
RU2283130C2 (ru) 2006-09-10
NZ519598A (en) 2004-03-26
HU229001B1 (en) 2013-07-29
CZ299232B6 (cs) 2008-05-21
US20020004047A1 (en) 2002-01-10
SK286384B6 (sk) 2008-08-05
US7887804B2 (en) 2011-02-15
US7893217B2 (en) 2011-02-22
CN1297566C (zh) 2007-01-31
NO20022836L (no) 2002-08-15
IL150115A (en) 2013-11-28
EE05293B1 (et) 2010-04-15
WO2001044291A3 (en) 2002-01-17
US20090214422A1 (en) 2009-08-27
SK288147B6 (sk) 2013-12-02
IL150115A0 (en) 2002-12-01
US6682902B2 (en) 2004-01-27
WO2001044291A2 (en) 2001-06-21
BG65898B1 (bg) 2010-04-30
JP2003521244A (ja) 2003-07-15
BG106823A (bg) 2003-04-30
MXPA02005914A (es) 2003-02-27
DK1237915T3 (da) 2009-11-16
US20040023307A1 (en) 2004-02-05
EP1237915B1 (en) 2009-08-26
EE200200323A (et) 2003-10-15
JP4979867B2 (ja) 2012-07-18
PL207634B1 (pl) 2011-01-31
DE60042836D1 (de) 2009-10-08
ATE440862T1 (de) 2009-09-15
RU2002119208A (ru) 2004-02-27

Similar Documents

Publication Publication Date Title
PL1629088T3 (pl) Warianty antygenu komórek macierzystych stercza (PSCA) i ich podsekwencje
BR0112542A (pt) Composições e métodos papa a terapia e a diagnose de câncer ovariano
WO2004016733A3 (en) Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
BR0113491A (pt) Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.
PT1200590E (pt) Antigénio transmembranar lectina tipo c expresso em cancro da próstata humano e utilizações do mesmo
AU2001287639A1 (en) Trp8, trp9 and trp10, markers for cancer
BR0308953A (pt) composições, proteìna, polinucleotìdeo, método de geração de uma resposta imune, método de detecção, composição farmacêutica, anticorpo ou seu fragmento, animal transgênico, hibridoma, método de fornecimento de um agente citotóxico ou agente de diagnóstico e método de inibição do crescimento de células cancerosas
DE69935220D1 (de) Von menschlichem tumor stammendes polypeptidhormon phosphatonin
CY1113064T1 (el) Νουκλεϊνικο οξυ και αντιστοιχη πρωτεϊνη με τιτλο 184ρ1ε2 χρησιμα στη θεραπεια και ανιχνευση καρκινου
ATE407147T1 (de) Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein
IL150115A (en) Isolated antibody that binds to rg1 polypeptides, immunosuppressant containing this antibody, antibody uses, and methods utilizing it
NZ516237A (en) Meth1 and meth2 polynucleotides and polypeptides
BR0312483A (pt) Anticorpos e seus usos
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2001081577A3 (en) Dna encoding the prost 03 polypeptide
ATE501255T1 (de) 84p2a9: prostata- und hodenspezifisches protein, das sehr stark bei prostatakrebs vorkommt
NZ502270A (en) Derivatives of mammalian secretory peptide-9 for treating cancer and may be used in conjunction with cytokines
WO2001098339A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
DK0970106T3 (da) uPAR-imiterende peptider
WO2001075021A3 (fr) Nouveau polypeptide, proteine humaine associee au transport de glucose 10, et polynucleotide codant pour ce polypeptide
WO2001075016A3 (en) A novel polypeptide, a human tyrosinase 16, and the polynucleotide encoding the polypeptide
WO2001079439A3 (fr) Nouveau polypeptide, proteine humaine de reception cannabinoide 19, et un polynucleotide codant pour ce polypeptide
WO2001094540A3 (en) A novel polypeptide, a human glucosyl hydrolase 23 and the polynucleotide encoding the polypeptide
WO2001075033A3 (fr) Veau polypeptide, proteine humaine 9 de regulation du cycle mi totique, et polynucleotide codant pour ce polypeptide
WO2001083685A3 (fr) Nouveau polypeptide, proteine cap 10, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees